The state of Ohio currently has 498 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Cincinnati, Columbus, Cleveland and Dayton.
Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC
NCT05363280
Recruiting
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Small Cell Lung Cancer
Register for Updates
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05478538
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Gabrail Cancer Center, Canton, Ohio
Conditions: Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Cleveland Clinic Akron General, Akron, Ohio +101 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Akron General Medical Center, Akron, Ohio +2 locations
Conditions: Breast Cancer
Register for Updates
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Toledo Clinic Cancer Center - Toledo, Toledo, Ohio
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831
Recruiting
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: OhioHealth Institute, Columbus, Ohio
Conditions: Endometrial Cancer
Register for Updates
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
NCT04638751
Recruiting
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 5,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the identification of clinically actionable cancer-specific biomarkers to guide therapeutic decisions. Four types of solid tumor cancers will be profiled including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) and pancreatic c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Kroger Health, The Little Clinic, Cincinnati, Ohio
Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Register for Updates
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
NCT04968548
Recruiting
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/28/2024
Locations: Summa Health, Akron, Ohio +1 locations
Conditions: Lung Cancer
Register for Updates
Amivantamab in Adenoid Cystic Carcinoma
NCT05074940
Recruiting
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Salivary Gland Cancer
Register for Updates
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
NCT05902533
Recruiting
To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Anal Cancer
Register for Updates
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881
Recruiting
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mort... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/15/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Register for Updates
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
NCT04372524
Recruiting
This study will validate a previously developed pediatric prognostic biomarker algorithm aimed at improving prediction of risk for the later development of chronic graft-versus-host disease (cGvHD) in children and young adults undergoing allogeneic hematopoietic stem cell transplant. By developing an early risk stratification of patients into low-, intermediate-, and high-risk for future cGvHD development (based upon their biomarker profile, before the onset of cGvHD), pre-emptive therapies aim... Read More
Gender:
ALL
Ages:
Between 0 years and 24 years
Trial Updated:
12/02/2023
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Register for Updates